Skip to main content

$3.18 0.09 (2.91%)

High

$3.18

Low

$3.12

Trades

1,177

Turnover

$3,954,133

Volume

1,248,327
30 June 2023 at 4:12pm
Register to track HLS and receive email alerts.

ASX Announcements (7d)

-

Twitter Mentions (7d)

0+

AFR Articles (7d)

1

News Articles (7d)

1+
Subject
HLS Article: Labor threatens pathology giants with price fixing probe over fee hike

HLS Article: Affinity PE closes $515m Lumus Imaging debt deal

HLS Article: Affinity Equity Partners last man standing in Healius’ Lumus auction

HLS Article: ASX falls; Brambles, Charter Hall soar

HLS Article: ASX falls; Charter Hall, Breville surge

HLS Article: Healius net losses double as it restructures, sells imaging unit

HLS Article: ASX to slip, Perpetual names new CEO, lower LNG prices hit Santos

HLS Article: Key bidder departs Healius’ $700m Lumus Imaging auction

HLS Article: PE titans lob bids for Healius’ $700m Lumus Imaging; UBS offers staple

HLS Article: Radiology’s AI future and deregulation help end years of bad blood

HLS Article: Healius to sell $650m X-ray and ultrasound division after UBS review

HLS Article: Why Rio Tinto is worth more than its $130 price tag

HLS Article: Healius in management shake-up after CEO exit

HLS Article: Making excuses for weak margins has ended: Healius CEO

HLS Article: Making excuses for weak margins has ended: Healius CEO

HLS Article: Making excuses for weak margins has ended: Healius CEO

HLS Article: Healius brings in UBS as it reviews strategy, considers asset sales

HLS Article: How a little acquisition exposed Healius’ core and has heads rolling

HLS Article: Healius CEO exits as strategic review speeds up

HLS Article: Healius flags asset sales and plans to shut some operations

HLS Article: ASX retreats, Coles jumps, defying profit drop

HLS Article: ASX edges lower; Oil spikes, Healius drops

HLS Article: John Wylie’s share fund draws new commitments, avenging down year

HLS Article: ACL pulls Healius bid as ACCC blocks pathology shake-up

HLS Article: Why it’s so hard to make money from blood tests

HLS Article: Healius chair exits without apology for $2b wipeout

HLS Article: Healius slammed over withheld patient data

HLS Article: Heads on sticks shows investors out of patience

HLS Article: Healius equity issue highlights need for long-term domestic debt

HLS Article: BGH Capital ready to bare its fangs at Healius over 2020 deal

HLS Article: Pezzullo sacked; Healius boss exits; Is Goldman wrong?

HLS Article: Healius chairwoman exits as ‘no’ vote looms

HLS Article: Miners drag ASX lower; QBE, Healius shares rally

HLS Article: ACL accuses Wylie of hiding links to independent Healius director

HLS Article: Healius boss says company’s economics have been upended as wages rise

HLS Article: Wylie’s Tanarra circulates Healius attack letter as shares slide

HLS Article: The Barclays Wimbledon box puts Healius in a spin

HLS Article: Banks sign off on healthcare group Healius’ long fall from grace

HLS Article: Dividend drought adds to pain for Healius shareholders

HLS Article: Terms out for Healius’ $187m rights issue

HLS Article: ASX rallies, buoyed by Regal Partners ahead of Fed meeting

HLS Article: ASX lifts, building approvals tumble 4.6pc; BHP bullish on potash

HLS Article: Struggling Healius backs former PE suitor’s bid for board seat

HLS Article: Lazard’s Hofflin is sticking with Healius despite ‘disappointment’

HLS Article: PEP, QIC run health check at Cura Day Hospitals; indicative bids land

HLS Article: Kerry Stokes trims Boral stake; Healius, City Chic kills dividend

HLS Article: ACCC inches closer to blocking $2b Healius-ACL merger proposal

HLS Article: Pathology dream deal a three-headed competition nightmare

HLS Ann: Notification regarding unquoted securities - HLS

HLS Article: Why Nathan Parkin is betting big on small caps

Register to track HLS and receive email alerts.

Similar Companies

AHX
BD1
CAJ
HLA
IDX
RHY
SHL
SLA
TTB